Can Novartis Convince Insurers a $2.1 Million Gene Therapy Is a Great Deal?
Getting end payers on board with a seven-figure price for Zolgensma won't be easy.
Sunday, May 26, 2019
Can Novartis Convince Insurers a $2.1 Million Gene Therapy Is a Great Deal?
Can Novartis Convince Insurers a $2.1 Million Gene Therapy Is a Great Deal?
Getting end payers on board with a seven-figure price for Zolgensma won't be easy.
0 comments:
Post a Comment